Initial Management of Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated prothrombotic disorder caused by antibodies against the heparin–platelet factor 4 (PF4) complex. The cornerstone of initial management is immediate cessation of all heparin (including flushes and heparin-coated catheters) and prompt initiation of a non-heparin anticoagulant, because the risk of thrombosis persists (and may even increase) despite low platelet counts.

Analysis of Each Option

• 1. Fondaparinux: A synthetic, indirect Factor Xa inhibitor that does not bind PF4 in a way that generates cross-reactive antibodies. It is widely used and recommended (off-label in many guidelines) as an alternative anticoagulant for the initial treatment of HIT, particularly in hemodynamically stable patients.
• 2. Rivaroxaban: An oral direct Factor Xa inhibitor (DOAC). Current evidence and updated guidance (including ASH guidelines) support the use of DOACs such as rivaroxaban and apixaban for both acute and subacute HIT management, especially once the patient is stable enough for oral therapy, making it an accepted option in initial management.
• 3. Lepirudin: A recombinant direct thrombin inhibitor (DTI) that was historically one of the first agents specifically approved for HIT. Direct thrombin inhibitors (lepirudin, argatroban, bivalirudin) are classic first-line parenteral options for acute HIT management.
• 4. Warfarin: Warfarin is contraindicated in the acute/initial phase of HIT. Because warfarin transiently depletes protein C (a natural anticoagulant with a short half-life) before it reduces the procoagulant factors II, IX, and X, starting warfarin during active thrombocytopenia can precipitate venous limb gangrene and skin necrosis. Warfarin should only be introduced later, after the platelet count has recovered to normal (generally >150,000/µL) and the patient has been adequately anticoagulated on a non-heparin agent for several days, with adequate overlap.

Conclusion

The agents appropriate for the initial management of HIT are the non-heparin anticoagulants that do not require prior platelet recovery: Fondaparinux (1), Rivaroxaban (2), and Lepirudin (3). Warfarin (4) is specifically avoided in the acute setting due to the risk of microthrombosis and limb gangrene.

Therefore, the correct answer is 1, 2 and 3.